Pfizer Inc on Monday announced that it would merge its off-patent drug business with generic drugmaker Mylan NV to create a global leader in low-cost treatment, a business that faces significant political pressure in the US.
The new entity, which is to be renamed upon the deal’s closure, would have a portfolio that includes impotence drug Viagra, cholesterol pills Lipitor, painkiller Lyrica and the life-saving EpiPen treatment for severe allergic reactions.
The merger comes amid rising competition in generic drugs from companies in India and elsewhere, a segment of pharma that is known for having low barriers to entry and commodity-like products.
Photo: AFP
Joining forces with Pfizer’s off-patent division, called Upjohn, would give Mylan access to more international markets.
The deal is also expected to result in US$1 billion in annual cost savings starting in 2023, the companies said.
“The combined organization will have a presence across nearly every continent and major market, establishing a new leadership position in Asia, and offering products capable of treating all major therapeutic areas,” said Mylan chairman Robert Coury, who is to serve as executive chairman of the new company.
This marks the latest move by Pfizer, which has grown into one of the world’s biggest pharma companies through a string of acquisitions.
The new company will be 57 percent owned by Pfizer shareholders and 43 percent owned by Mylan investors.
Upjohn president Michael Goettler is to serve as CEO of the new firm, while Mylan CEO Heather Bresch is to leave the company.
Pfizer, meanwhile, has announced deals in recent months to combine its consumer healthcare business with GlaxoSmithKline PLC’s unit, and to spend US$11.4 billion to acquire Array BioPharma Inc, which is known for drugs in development focused on oncology and rare disease.
Pfizer chief executive Albert Bourla said the deal with Mylan would sharpen the company’s focus on “breakthroughs that change patients’ lives.”
Separately, Pfizer reported that second-quarter profit jumped 30.3 percent to US$5 billion, due in part to a large one-time boosts from a favorable US tax settlement and a lower tax rate after the late 2017 US tax cut signed by US President Donald Trump.
Revenues dropped 1.5 percent to US$13.3 billion.
Pfizer also cut some of its financial forecasts for this year, citing the accounting of the GlaxoSmithKline and Array transactions.
Mylan’s share price surged 12.6 percent to end the day at US$20.78, while Pfizer fell 3.8 percent to US$41.45.
NEW MARKET: The partnership opens up India to the Dutch company, which already has a strong hold in the semiconductor market of South Korea, Taiwan and China ASML Holding NV entered into a partnership agreement with Tata Electronics Pvt Ltd aimed at ramping up India’s goal to develop domestic chip-manufacturing capabilities. The Dutch company’s technology would help power Tata Electronics’ planned 300 millimeter (mm) semiconductor foundry in Gujarat, according to a joint statement from the two companies on Saturday. The signing of a memorandum of understanding coincides with a visit by Indian Prime Minister Narendra Modi to the Netherlands, which is looking to deepen bilateral relations with New Delhi. ASML, whose top customers include Taiwan Semiconductor Manufacturing Co (台積電) and Samsung Electronics Co, makes lithography machines that can print
ROUGH RECORDS: Bonds in Japan, as well is in New Zealand, Australia and the US, are seeing the effects of a nervy market as stock exchanges across Asia edge down A deepening slump in Japanese government bonds added fuel to the selloff in global debt markets as rising oil prices stoked inflation fears and pushed yields to multi-decade highs. Japan’s 30-year yield yesterday surged as much as 20 basis points to the highest level since the tenor’s debut in 1999, before paring some of the move. Shorter-maturity Japanese debt was also under pressure, underscored by weak demand at a sale of five-year notes that offered a record-high coupon of 2 percent. Concerns over inflation and government spending rippling through markets including the US, Australia and New Zealand are being amplified in Japan,
The US has cleared about 10 Chinese firms to buy Nvidia Corp’s second-most powerful artificial intelligence (AI) chip, the H200, but not a single delivery has been made so far, three people familiar with the matter said, leaving a major technology deal in limbo as chief executive officer Jensen Huang (黃仁勳) seeks a breakthrough in China this week. Huang, who was not initially listed in a White House delegation to Beijing, joined the trip after an invitation from US President Donald Trump, a source said. Trump picked him up in Alaska en route to a summit with Chinese President Xi Jinping
Wall Street is licking its chops over an unprecedented slate of massive initial public offerings (IPOs) set to arrive in the coming months, beginning with Elon Musk’s Space Exploration Technologies Corp (SpaceX) next month. That is expected to be followed by artificial intelligence (AI) rivals OpenAI and Anthropic PBC. The trio of mega listings, each eyeing valuations around US$1 trillion or more, constitutes a heady period of elevated risk and reward. SpaceX is targeting an IPO that would raise up to US$80 billion — about double the funds generated from all IPOs last year. OpenAI and Anthropic are eyeing IPOs raising US$60 billion. “We’re
RSS